DARE to PLAY™ Sildenafil Cream: Breakthrough Treatment for Female Sexual Arousal Issues

madman · Dec 9, 2025

What makes DARE to PLAY™ different than the other creams?

In this video, experts Dr. James Simon and Dr. Sheryl Kingsberg break down the science, clinical data, and innovative formulation behind this first-of-its-kind treatment designed to support women experiencing arousal challenges.

What You’ll Learn:

* The biology of female arousal

* How and why arousal issues can impact women’s sexual health and well-being

* The clinical data behind DARE to PLAY™ Sildenafil Cream

* Why this groundbreaking formulation raises the bar for women’s sexual health

Whether you're a clinician, researcher, or someone seeking evidence-based information, this discussion offers trusted insights into an emerging therapeutic option.

madman · Dec 9, 2025

Thread 'Safety of topical sildenafil cream, 3.6% for the treatment of female sexual arousal disorder'

Jul 31, 2024

Abstract

Background

There are currently no Food and Drug Administration–approved treatments for female sexual arousal disorder (FSAD), which is physiologically analogous to male erectile dysfunction.

Aims

The study sought to test the systemic and local genital safety of topical sildenafil cream, 3.6% (sildenafil cream) among healthy premenopausal women with FSAD and their sexual partners over a 12-week treatment period.

Methods

This was a phase 2b, exploratory, randomized, placebo-controlled, double-blind study of sildenafil cream among...

Thread 'Topical sildenafil cream found safe, tolerable in female sexual arousal disorder'

Sep 7, 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder | Urology Times

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

www.urologytimes.com

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

Topical sildenafil cream (3.6%) was found to be safe and well-tolerated among premenopausal women with female sexual arousal disorder (FSAD) and their sexual partners, according to safety data from the phase 2b RESPOND trial (NCT04948151) published...